A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2411-2416

  Rustin, G ^a   Reed, N ^b   Jayson, G C ^c   Ledermann, J A ^d   Adams, M ^e   Perren, T ^f   Poole, C ^g   Lind, M ^h   Persic, M ⁱ   Essapen, S ^j   Gore, M ^k   Calvert, H ^d   Stredder, C ^l   Wagner, A ^m   Giurescu, M ^m   Kaye, S ^k  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Velindre NHS Trust   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^h Princess Royal Hospital Hull   (United Kingdom)

ⁱ DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^j ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^k INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^l Bayer plc UK   (United Kingdom)

^m BAYER PHARMA AG   (Germany)

more..

Author keywords

Epothilone; Ovarian cancer; Phase II; Sagopilone

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; SAGOPILONE; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEG PAIN; LETHARGY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

EID: 80155174272     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq780     Document Type: Article

References (27)

1. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005; 17: 399-411.
2. Hoffmann J, Vitale I, Buchmann B et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68: 5301-5308.
3. Klar U, Buchmann B, Schwede W et al. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006; 45: 7942-7948.
4. Gatzemeier U, von Pawel J, Eschbach C et al. Phase II trial of the novel epothilone sagopilone (ZK-EPO) as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. Poster P-6568 presented at the ECCO 14. Barcelona, Spain,23-27 September, 2007.
5. Schmid P, Kiewe P, Possinger K et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010; 21: 633-639.
6. Arnold D, Voigt W, Kiewe P et al. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 2009; 101: 1241-1247.
7. McMeekin S, Patel R, Verschraegen C et al. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Ann Oncol 2008; 19 (Suppl 8): viii211 (Abstr 665O).
8. Mielke S, Mross K, Glocker F-X et al. Neurotoxicity of paclitaxel infused weekly over one versus three hours: preliminary results of a phase III trial. Proc Am Soc Clin Oncol 2001; 20: (Abstr 425).
9. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415-3420.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
11. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008; 6: 455-467.
12. Roché HH, Cure H, Bunnell C et al. A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 2003; 22: 18 (Abstr 69).
13. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007; 21 (Suppl 1): 39-43.
14. Gelderblom H, Verweij J, Nooter K et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598.
15. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-685.
16. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 2004; 9: 33-42.
17. Chen T, Molina A, Moore S et al. Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. J Clin Oncol (Meeting Abstracts) 2004; 22: (Abstr 2115).
18. Smit WM, Sufliarsky J, Werner TL et al. A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. J Clin Oncol (Meeting Abstracts) 2009; 27: 292s (Abstr 5563).
19. ten Bokkel Huinink WW, Sufliarsky J, Smit WM et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 2009; 27: 3097-3103.
20. Colombo N, Schwartz PE, Bamias A et al. Results of a randomized, open-label, phase III trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian, or peritoneal cancer. Ann Oncol 2010; 21 (Suppl 8): viii11 (Abstr LBA24).
21. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
22. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193.
23. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-2410.
24. Vergote I, Finkler N, del Campo J et al. Canfosfamide (C, TLK286) versus liposomal doxorubicin (D) or topotecan (T) in the third-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): results of a phase III study. J Clin Oncol (Meeting Abstracts) 2007; 25: 281s (Abstr LBA5528).
25. Markman M, Blessing J, Rubin SC et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101: 436-440.
26. Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97: 1618-1624.
27. Miller DS, Blessing JA, Krasner CN et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009; 27: 2686-2691.